Healthcare Global Enterprises Limited — PPTs, 06-08-2026: Investor Presentation

HCG delivered robust Q1 FY27 results, with revenue up 13% YoY to ₹695.1 Cr and Adjusted EBITDA growing 20% YoY to ₹133.9 Cr, pushing margins to 19.4%. Profit after Tax surged 190% YoY to ₹13.8 Cr, with EPS at ₹0.92. Patient volumes increased 11%, driving broad-based growth across South (+16%), West (+9%), and East (+22%) regions.

Strategically, HCG sharpened its focus on core oncology by divesting the fertility business. It's actively expanding capacity, adding 121 operational beds this quarter, including the new North Bangalore facility (56 beds) which commissioned an MR Linac in July. Other developments include upgrading Rajkot to a Comprehensive Cancer Care Centre and expanding robotic surgery capabilities.

Management's outlook centers on accelerating profitable revenue growth, optimizing network efficiency through cost management, and disciplined capital allocation. The company aims for 1,000 beds by FY30, primarily through brownfield expansions, emphasizing continuous investment in technology and patient experience.